Peer-reviewed veterinary case report
Monocytes linked to spread of hemangiosarcoma tumors in dogs
By Regan, D P et al.·Published in Veterinary and comparative oncology·2017·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Role of monocyte recruitment in hemangiosarcoma metastasis in dogs.
- Species:
- dog
Plain-English summary
A study found that dogs with hemangiosarcoma, a serious and aggressive type of cancer, have a higher number of certain immune cells called monocytes in their tumors compared to other types of cancer. These monocytes may help the cancer spread more quickly. The researchers discovered that hemangiosarcoma cells produce a chemical that attracts these monocytes, which could explain why this cancer is so aggressive. They suggest that treatments aimed at blocking the recruitment of these immune cells might help slow down the spread of hemangiosarcoma in dogs.
People also search for: dog hemangiosarcoma treatment · why is my dog losing weight · dog cancer survival rates · monocytes in dog tumors · hemangiosarcoma symptoms in dogs
Abstract
Canine hemangiosarcoma (HSA) is a highly malignant tumour associated with short survival times because of early and widespread metastasis. In humans and rodents, monocytes play key roles in promoting tumour metastasis through stimulating tumour cell extravasation, seeding, growth and angiogenesis. Therefore, we investigated the potential association between monocyte infiltration and tumour metastasis in HSA and other common canine tumours. Immunohistochemistry was used to quantify CD18monocytes within metastases. We found that HSA metastases had significantly greater numbers of CD18monocytes compared with metastases from other tumour types. HSA cells were the highest producers of the monocyte chemokine CCL2, and stimulated canine monocyte migration in a CCL2 dependent manner. These results are consistent with the hypothesis that overexpression of CCL2 and recruitment of large numbers of monocytes may explain in part the aggressive metastatic nature of canine HSA. Thus, therapies designed to block monocyte recruitment may be an effective adjuvant strategy for suppressing HSA metastasis in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27779362/